Literature DB >> 16771808

Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.

P Sharma1, A M Harper, J L Hernandez, T Heffron, D C Mulligan, R H Wiesner, V Balan.   

Abstract

The liver organ allocation policy of the United Network for Organ Sharing (UNOS) is based on the model for end-stage liver disease (MELD). The policy provides additional priority for candidates with hepatocellular carcinoma (HCC) who are awaiting deceased donor liver transplantation (DDLT). However, this priority was reduced on February 27, 2003 to a MELD of 20 for stage T1 and of 24 for stage T2 HCC. The aim of this study was to determine the impact of reduced priority on HCC candidate survival while on the waiting list. The UNOS database was reviewed for all HCC candidates listed after February 27, 2002, The HCC candidates were grouped into two time periods: MELD 1 (listed between February 27, 2002, and February 26, 2003) and MELD 2 (listed between February 27, 2003 and February 26, 2004). For the two time periods, the national DDLT incidence rates for HCC patients were 1.44 versus 1.53 DDLT per person-year (p = NS) and the waiting times were similar for the two periods (138.0 +/- 196.8 vs. 129.0 +/- 133.8 days; p = NS). Furthermore, the 3-, 6- and 12-month candidate, patient survival and dropout rates were also similar nationally. Regional differences in rates of DDLT for HCC were observed during both MELD periods. Consequently, the reduced MELD score for stage T1 and T2 HCC candidates awaiting DDLT has not had an impact nationally either on their survival on the waiting list or on their ability to obtain a liver transplant within a reasonable time frame. However, regional variations point to the need for reform in how organs are allocated for HCC at the regional level.

Entities:  

Mesh:

Year:  2006        PMID: 16771808     DOI: 10.1111/j.1600-6143.2006.01411.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

1.  Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Authors:  Pratima Sharma; Kathy Welch; Hero Hussain; Shawn J Pelletier; Robert J Fontana; Jorge Marrero; Robert M Merion
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.

Authors:  Julie K Heimbach; Ryutaro Hirose; Peter G Stock; David P Schladt; Hui Xiong; Jiannong Liu; Kim M Olthoff; Ann Harper; Jon J Snyder; Ajay K Israni; Bertram L Kasiske; W Ray Kim
Journal:  Hepatology       Date:  2015-02-24       Impact factor: 17.425

3.  MELD-good for many, not as good for others … at least for now.

Authors:  Thomas Schiano
Journal:  Hepatol Int       Date:  2012-07-25       Impact factor: 6.047

Review 4.  Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future?

Authors:  Haniee Chung; William C Chapman
Journal:  Hepat Oncol       Date:  2014-09-09

Review 5.  Surgical treatment of hepatocellular carcinoma: expert consensus statement.

Authors:  William Jarnagin; William C Chapman; Steven Curley; Michael D'Angelica; Charles Rosen; Elijah Dixon; David Nagorney
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

6.  Venous Thrombotic Events After Liver Transplantation.

Authors:  Annabel Blasi; Virginia Hernandez; Javier Fernandez; Jordi Colmenero; Joan Beltran; Juan Carlos Garcia-Valdecasas; Joan Carles Reverter
Journal:  Clin Appl Thromb Hemost       Date:  2016-11-28       Impact factor: 2.389

Review 7.  The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

Authors:  Yoichi Ishizaki; Seiji Kawasaki
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

8.  Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients.

Authors:  Pratima Sharma; Neehar D Parikh; Jessica Yu; Pranab Barman; Brian A Derstine; Christopher J Sonnenday; Stewart C Wang; Grace L Su
Journal:  Liver Transpl       Date:  2016-06-29       Impact factor: 5.799

9.  Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC.

Authors:  Rahul Deshpande; Derek O'Reilly; David Sherlock
Journal:  Int J Hepatol       Date:  2011-06-12

10.  Hepatocellular carcinoma: focus on different aspects of management.

Authors:  Sene Waly Raphael; Zhang Yangde; Chen Yuxiang
Journal:  ISRN Oncol       Date:  2012-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.